These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 16357568)

  • 1. Oncogenic PI3K and its role in cancer.
    Samuels Y; Ericson K
    Curr Opin Oncol; 2006 Jan; 18(1):77-82. PubMed ID: 16357568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
    Oda K; Okada J; Timmerman L; Rodriguez-Viciana P; Stokoe D; Shoji K; Taketani Y; Kuramoto H; Knight ZA; Shokat KM; McCormick F
    Cancer Res; 2008 Oct; 68(19):8127-36. PubMed ID: 18829572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy.
    Saintigny P; Mitani Y; Pytynia KB; Ferrarotto R; Roberts DB; Weber RS; Kies MS; Maity SN; Lin SH; El-Naggar AK
    Cancer; 2018 Sep; 124(18):3693-3705. PubMed ID: 30289966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review).
    Hafsi S; Pezzino FM; Candido S; Ligresti G; Spandidos DA; Soua Z; McCubrey JA; Travali S; Libra M
    Int J Oncol; 2012 Mar; 40(3):639-44. PubMed ID: 22200790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
    De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G
    PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
    Chen L; Yang L; Yao L; Kuang XY; Zuo WJ; Li S; Qiao F; Liu YR; Cao ZG; Zhou SL; Zhou XY; Yang WT; Shi JX; Huang W; Hu X; Shao ZM
    Nat Commun; 2018 Apr; 9(1):1357. PubMed ID: 29636477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN-deficient cancers depend on PIK3CB.
    Wee S; Wiederschain D; Maira SM; Loo A; Miller C; deBeaumont R; Stegmeier F; Yao YM; Lengauer C
    Proc Natl Acad Sci U S A; 2008 Sep; 105(35):13057-62. PubMed ID: 18755892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
    Tserga A; Chatziandreou I; Michalopoulos NV; Patsouris E; Saetta AA
    Virchows Arch; 2016 Jul; 469(1):35-43. PubMed ID: 27059323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma.
    Demicco EG; Torres KE; Ghadimi MP; Colombo C; Bolshakov S; Hoffman A; Peng T; Bovée JV; Wang WL; Lev D; Lazar AJ
    Mod Pathol; 2012 Feb; 25(2):212-21. PubMed ID: 22020193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
    Vasudevan KM; Barbie DA; Davies MA; Rabinovsky R; McNear CJ; Kim JJ; Hennessy BT; Tseng H; Pochanard P; Kim SY; Dunn IF; Schinzel AC; Sandy P; Hoersch S; Sheng Q; Gupta PB; Boehm JS; Reiling JH; Silver S; Lu Y; Stemke-Hale K; Dutta B; Joy C; Sahin AA; Gonzalez-Angulo AM; Lluch A; Rameh LE; Jacks T; Root DE; Lander ES; Mills GB; Hahn WC; Sellers WR; Garraway LA
    Cancer Cell; 2009 Jul; 16(1):21-32. PubMed ID: 19573809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.
    Ligresti G; Militello L; Steelman LS; Cavallaro A; Basile F; Nicoletti F; Stivala F; McCubrey JA; Libra M
    Cell Cycle; 2009 May; 8(9):1352-8. PubMed ID: 19305151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis.
    Kennedy AL; Morton JP; Manoharan I; Nelson DM; Jamieson NB; Pawlikowski JS; McBryan T; Doyle B; McKay C; Oien KA; Enders GH; Zhang R; Sansom OJ; Adams PD
    Mol Cell; 2011 Apr; 42(1):36-49. PubMed ID: 21474066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of p53-dependent growth suppression in human cells by mutations in PTEN or PIK3CA.
    Kim JS; Lee C; Bonifant CL; Ressom H; Waldman T
    Mol Cell Biol; 2007 Jan; 27(2):662-77. PubMed ID: 17060456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.
    Kinross KM; Montgomery KG; Kleinschmidt M; Waring P; Ivetac I; Tikoo A; Saad M; Hare L; Roh V; Mantamadiotis T; Sheppard KE; Ryland GL; Campbell IG; Gorringe KL; Christensen JG; Cullinane C; Hicks RJ; Pearson RB; Johnstone RW; McArthur GA; Phillips WA
    J Clin Invest; 2012 Feb; 122(2):553-7. PubMed ID: 22214849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations.
    Tanaka H; Yoshida M; Tanimura H; Fujii T; Sakata K; Tachibana Y; Ohwada J; Ebiike H; Kuramoto S; Morita K; Yoshimura Y; Yamazaki T; Ishii N; Kondoh O; Aoki Y
    Clin Cancer Res; 2011 May; 17(10):3272-81. PubMed ID: 21558396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncogenic activation of the PI3-kinase p110β isoform via the tumor-derived PIK3Cβ(D1067V) kinase domain mutation.
    Pazarentzos E; Giannikopoulos P; Hrustanovic G; St John J; Olivas VR; Gubens MA; Balassanian R; Weissman J; Polkinghorn W; Bivona TG
    Oncogene; 2016 Mar; 35(9):1198-205. PubMed ID: 25982275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression-free survival.
    Rogers HA; Mayne C; Chapman RJ; Kilday JP; Coyle B; Grundy RG
    Clin Cancer Res; 2013 Dec; 19(23):6450-60. PubMed ID: 24077346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.